Farampator

Chemical compound

US: Investigational New Drug

Identifiers

IUPAC name

2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone

CAS Number

211735-76-1^Y

PubChem CID

4118151

ChemSpider

3331565^N

UNII

7X6P5N8K2L

KEGG

D04131^Y

CompTox Dashboard (EPA)

DTXSID90175413

Chemical and physical dataFormulaC₁₂H₁₃N₃O₂Molar mass231.255 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2

InChI

InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2^N
Key:XFVRBYKKGGDPAJ-UHFFFAOYSA-N^N

^NY (what is this?) (verify)

Farampator (developmental code names CX-691, ORG-24448, SCH-900460) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity.^[1]^[2]

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects such as headache, somnolence and nausea. Subjects reporting side effects had significantly higher plasma levels of farampator than subjects without.^{[citation needed]} Additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects.^[3]

References

^ "Farampator - AdisInsight".
^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
^ Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG (Jun 2007). "Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers". Neuropsychopharmacology. 32 (6): 1272–83. doi:10.1038/sj.npp.1301257. PMID 17119538.